New York healthcare startups received $3.9 billion of funding in 2022, compared to $9 billion in 2021, according to a new DHNY report. Biotech startups represented 22% of total funding in 2022, a stark difference from women’s health only representing 2%.
Read about executive hires across healthcare and life sciences.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
By all accounts, Ro is a successful direct-to-consumer telehealth and pharmacy services startup. At the recently-concluded HLTH conference, Ro's chief medical officer speculated on how it might enter the business-to-business healthcare world.
Eddie Peloke, CEO of Workpath, spoke to why in-home care can drive the next stage of this industry-wide movement
The direct-to-consumer health startup recently acquired Modern Fertility, a startup with a similar business model. The startup’s founders will lead Ro’s women’s health business.
Ro, a direct-to-consumer health startup, recently raised a $500 million funding round. It plans to use the funds to expand into at-home diagnostics and care.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Direct-to-consumer health startup Ro is reportedly in talks go public through a merger with a blank-check company, according to a report by Reuters.
Ro, a startup offering patients mail-order prescriptions and telehealth appointments, raised $200 million in funding. The company started three years ago with men’s health and wellness products, before expanding its business.
Healthcare investing reached record new highs in 2018, hitting more than $30 billion across all sectors, according to numbers from Pitchbook.
Ro, previously known as Roman, has raised the new money to launch a smoking cessation vertical called Zero.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.